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Introduction: It is unclear whether the fluid status, as determined by bioimpedance vector analysis (BIVA)
combined with serum N-terminal pro-B-type natriuretic peptides (NT-pro-BNP) measurement, is associated with
treatment outcome among patients receiving continuous renal replacement therapy (CRRT). Our objective was to
answer this question.
Methods: Patients who were in the intensive care units of a university teaching hospital and who required CRRT
were screened for enrollment. For the enrolled patients, BIVA and serum NT-pro BNP measurement were performed
just before the start of CRRT and 3 days afterward. According to the BIVA and NT-pro BNP measurement results,
the patients were divided into four groups according to fluid status type: type 1, both normal; type 2, normal BIVA
results and abnormal NT-pro BNP levels; type 3, abnormal BIVA results and normal NT-pro BNP levels; and type 4,
both abnormal. The associations between fluid status and outcome were analyzed.
Results: Eighty-nine patients were enrolled, 58 were males, and the mean age was 49.0 ± 17.2 years. The mean
score of Acute Physiology and Chronic Health Evaluation II (APACHE II) was 18.8 ± 8.6. The fluid status before CRRT
start was as follows: type 1, 21.3% (19 out of 89); type 2, 16.9% (15 out of 89); type 3, 11.2% (10 out of 89); and type
4, 50.6% (45 out of 89). There were significant differences between fluid status types before starting CRRT on
baseline values for APACHE II scores, serum creatinine, hemoglobin, platelet count, urine volume, and incidences of
oliguria and acute kidney injury (P <0.05). There were significant differences between patients with different fluid
status before CRRT start on hospital mortality—type 1, 26.3% (5 out of 19); type 2, 33.3% (5 out of 15); type 3, 40%
(4 out of 10); and type 4, 64.4% (29 out of 45) (P = 0.019)—as well as renal function recovery rates: type 1, 57.1%
(4 out of 7); type 2, 67.7% (6 out of 9); type 3, 50% (3 out of 6); and type 4, 23.7% (9 out of 38) (P = 0.051).
Conclusions: Fluid status abnormalities were common among patients receiving CRRT. Different types of fluid
status distinguished by BIVA combined with serum NT-pro BNP measurements corresponded to different clinical
conditions and treatment outcomes, which implies a value of this method for evaluation of fluid status among
patients receiving CRRT.* Correspondence: gong_doctor@126.com
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Fluid overload is a risk factor for mortality among critic-
ally ill patients. As reported in an observational study
using data generated by the RENAL (Randomized Evalu-
ation of Normal versus Augmented Level) trial, a nega-
tive mean daily fluid balance was consistently associated
with improved clinical outcomes [1]. For patients receiv-
ing continuous renal replacement therapy (CRRT) due
to the loss of renal capacity, fluid balance is largely
dependent on decisions of the attending physician which
are based on an accurate fluid status assessment. How-
ever, there is no consensus on an effective method to
evaluate fluid status.
The most commonly used methods to calculate daily
fluid balance, such as monitoring changes in body weight,
are obviously imprecise with pronounced diversity be-
tween different methods [2]. Bioimpedance vector analysis
(BIVA) is a recently proposed method for fluid status as-
sessment because of the advantages of non-invasiveness,
convenience, low cost, real-time measurements, and good
reproducibility [3,4]. Theoretically, BIVA reflects tissue
hydration (that is, static fluid load), which is not always in
accordance with blood volume or cardiac function. Serum
N-terminal pro-B-type natriuretic peptide (NT-pro BNP),
which is produced by cardiomyocytes under stretching
stress, reflects cardiac reaction to volume load and acts as
a biomarker for diagnosis of heart failure [5]. However,
serum NT-pro BNP does not reflect tissue hydration sta-
tus. Therefore, the differentiation of ‘wet BNP’ (induced
by acute pressure or volume overload) from ‘dry BNP’
(baseline, euvolemic) has been suggested to improve as-
sessment of fluid status in clinical practice [6]. Apparently,
either BIVA or NT-pro BNP only partially reflects fluid
status; thus, the combined use of these parameters may
offer more precise information about fluid status. How-
ever, there are no data on the combined use of BIVA and
NT-pro BNP to assess fluid status in patients receiving
CRRT.
In the present study, we assessed fluid status among
patients receiving CRRT by using BIVA combined with
serum NT-pro BNP and identified correlations between
outcome and fluid status, as determined by the combin-
ation of these two parameters.
Methods
Patients
From April 2013 to March 2014, all patients requiring
CRRT in Jinling Hospital (Nanjing University School of
Medicine, Nanjing, China) were screened for enrollment.
The inclusion criteria were age of more than 18 years,
admission to the intensive care unit, and the require-
ment of CRRT, and the exclusion criteria were the pres-
ence of malignant disease, pregnancy, history of end-
stage renal disease, and burn injury. The study protocolwas previously approved by the Ethics Committee of
Jinling Hospital, and informed consent was obtained
from each patient or next of kin before participation.
The treatment protocol, including CRRT and prescribed
medications to maintain volume balance, remained un-
changed after enrollment.
Continuous renal replacement therapy protocol
A central venous catheter was used for blood access at a
blood flow rate of 160 to 200 mL/minute. Pre-dilution
continuous hemofiltration (CVVH) was performed by
using a polysulphone filter (AV600S; Fresenius SE & Co.
KGaA, Bad Homburg, Germany), with a replacement
fluid infusion rate of 2,000 to 3,000 mL/hour. Regional
citrate anticoagulation combined with low-dose heparin
was used to maintain activated clotting time within the
extracorporeal circuit in a desired range (200 to 250 sec-
onds). Daily net ultrafiltration volume was determined
by the attending physician.
Data collection
BIVA evaluation and serum NT-pro BNP measurement
were performed for all participants just before the start of
CRRT and 3 days later. The clinical status, incidence of
acute kidney injury (AKI), hospital mortality, and renal
function recovery were recorded. Right-sided whole-body
impedance, including resistance and reactance, was
measured by using a Bodystat QuadScan 4000 device
(Bodystat Ltd., Isle of Man, UK) at a frequency of 50 kHz.
In accordance with the instructions of the manufacturer, a
tetrapolar wrist-to-ankle method was used, in which a pair
of electrodes was placed approximately 5 mm apart on the
dorsal surface of the right wrist and ipsilateral ankle, with
the patient in the supine position. The hydration status
was determined by plotting the point vector on the refer-
ence bivariate tolerance ellipses (RXc point graph). Vector
displacements parallel to the major axis of tolerance ellip-
ses indicate progressive changes in tissue hydration, in
which short vectors out of the lower pole (falling out of
the 75% tolerance ellipse) indicate overhydration [7].
Serum NT-Pro BNP was detected in our hospital labora-
tory by using electrochemical luminescence immunoassay
analysis (Cobas assay; Roche Diagnostics, Mannheim,
Germany), with a level of more than 106.2 pmol/L (the
normal range provided by the hospital lab) considered
abnormal. AKI was diagnosed according to the KDIGO
(Kidney Disease: Improving Global Outcomes) criteria [8],
and renal recovery was defined as a return of creatin-
ine to pre-morbid renal function levels (serum creatinine
(sCr) <1.5 × premorbid sCr) within 3 months.
Fluid status assessment
According to the results of BIVA and serum NT-pro
BNP measurements, fluid status was divided into four
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elevation of NT-pro BNP; type 2, no overhydration with
abnormal NT-pro BNP levels; type 3, overhydration with
normal NT-pro BNP levels; and type 4, overhydration
with abnormal NT-pro BNP levels.
Statistical analysis
Continuous variables with a normal distribution are pre-
sented as the mean (± standard deviation) and compared
between groups by using the Student’s t test. Continuous
variables with a skewed distribution are presented as the
median (range) and compared between groups by using
the rank-sum test. Categorical variables are expressed as
number (percentage) and compared between groups by
using the chi-squared test. Survival curves were gener-
ated by using the Kaplan-Meier method and compared
by using the log-rank test. Univariate and multivariate
adjusted logistic regression analyses were performed to
determine whether NT-ProBNP, BIVA, or both was an
independent risk factor for mortality. Data were analyzed
by using SAS version 9.2 statistical software (SAS Insti-
tute Inc., Cary, NC, USA). A two-sided P value of less
than 0.05 was considered statistically significant.
Results
In total, 89 patients, including 58 males, with a mean
age of 49.0 ± 17.2 years were enrolled in this study. The
primary diseases were as follows (Table 1): intestinal fis-
tula and associated intra-abdominal infection (n = 27,
30.3%), severe acute pancreatitis (n = 28, 31.5%), trauma
(n = 8, 9.0%), acute liver failure (n = 4, 4.5%), pulmonary
infection (n = 9, 10.1%), and other diseases (n = 13,
14.6%). Among them, the incidences of multiple organ
dysfunction syndrome, sepsis, and AKI were 76.4% (n =
68), 21.3% (n = 19), and 67.4% (n = 60), respectively. The
mean score of the Acute Physiology and Chronic Health
Evaluation II (APACHE II) was 18.8 ± 8.6. The mean
CRRT duration was 8.0 ± 8.2 days. Among the 60 pa-
tients with AKI, 22 (36.7%) achieved recovery of renal
function. Forty-three (48.3%) patients died before dis-
charge. Seventy patients completed second volume sta-
tus evaluations, and the others dropped out within
3 days after the start of CRRT, which included 15 who
died and four who were discharged.
Correlations between pre-continuous renal replacement
therapy fluid status and clinical conditions and outcomes
The fluid status prior to the start of CRRT was as fol-
lows: type 1, 19 cases (21.3%); type 2, 15 cases (16.9%);
type 3, 10 cases (11.2%); and type 4, 45 cases (50.6%). As
shown in Table 1, the clinical conditions of patients
revealed significant differences between types of fluid
status according to APACHE II scores, serum creatinine
levels, hemoglobin concentrations, platelet counts, urinevolume, and incidences of oliguria and AKI (P <0.05).
Although there were no differences between fluid status
types on mortality on day 3, there were significant differ-
ences in hospital mortality as well as renal function re-
covery (Table 2). Kaplan-Meier survival curve analysis
revealed that the survival rate of patients classified as
type 4 fluid status was lower than in the other groups
(Figure 1, P = 0.0252).
Changes in fluid status after start of continuous renal
replacement therapy
A second fluid status evaluation was performed for 70
patients 3 days after beginning CRRT. Patient mortality
according to fluid status on day 3 was as follows: type 1,
25% (4 out of 16), type 2, 25% (3 out of 12), type 3, 40%
(4 out of 10), and type 4, 60% (18 out of 30) (Table 3,
P = 0.051). Similar to the results of primary fluid sta-
tus, the highest mortality was among patients with type 4
fluid status on day 3. For patients with type 4 fluid status
before CRRT, those with continued type 4 fluid status on
day 3 had high mortality (14 out of 20), whereas those
with improvement in one parameter of fluid status on day
3 had the lowest mortality (1 out of 5 and1 out of 4) and
those with improvements in both two parameters of fluid
status (change to type 1 fluid status) had the highest
mortality (3 out of 4).
Relationship between mortality and N-terminal
pro-B-type natriuretic peptide or bioimpedance vector
analysis or both
Univariate logistic regression analyses indicated that age,
APACHE II score, AKI, acute heart failure, severe sepsis,
mechanical ventilation, overhydration on day 1, high
NT-ProBNP on day 1, and overhydration plus high NT-
ProBNP on day 1 were potential risk factors for mortal-
ity. However, in the multivariate adjusted analyses, only
APACHE II score was an independent risk factor for
mortality (Table 4). Furthermore, multivariate adjusted
analyses using NT-Pro BNP and BIVA on day 3 revealed
that only APACHE II score was an independent risk fac-
tor for mortality (data not shown).
Discussion
In this prospective observational study, fluid status was
evaluated by using the combination of BIVA and NT-Pro
BNP measurement, which revealed a frequent occurrence
of abnormal fluid status (70/89) in patients receiving
CRRT, and four types of fluid status corresponded to dif-
ferent clinical conditions and treatment outcomes. Al-
though fluid status was not an independent risk factor for
mortality in this study, changes in fluid status and mortal-
ity implied potential value of this method for fluid status
evaluation in patients receiving CRRT. However, we have
to acknowledge the major weakness of the study: the
Table 1 Clinical conditions between different types of fluid status before continuous renal replacement therapy
Fluid status Total Type 1 Type 2 Type 3 Type 4 P value
Number (%) 89 (100) 19 (21.3) 15 (16.9) 10 (11.2) 45 (50.6)
Male/female 58/31 13/6 9/6 9/1 27/18 0.319
Age, years 49.0 ± 17.2 45.5 ± 15.1 44.7 ± 16.6 43.3 ± 17.9 53.1 ± 17.7 0.148
Height, cm 167.9 ± 10.4 168.5 ± 7.0 166.2 ± 8.8 176.9 ± 6.2 166.4 ± 12.0 0.015
Weight, kg 70.4 ± 15.8 69.0 ± 23.1 63.2 ± 10.0 78.5 ± 14.5 72.0 ± 12.7 0.023
Primary reason for hospitalization, n (%)
Pancreatic 28 (31.4) 11 (57.9) 2 (13.3) 4 (40.0) 11 (24.4) 0.021
Gastrointestinal 27 (30.3) 5 (26.3) 3 (20.0) 4 (40.0) 15 (33.3) 0.678
Liver 4 (4.5) 2 (10.5) 1 (6.7) 0 1 (2.2) 0.431
Pulmonary 9 (10.1) 0 3 (20.0) 1 (10.0) 5 (11.1) 0.289
Trauma 8 (9.0) 0 1 (6.7) 1 (10.0) 6 (13.3) 0.393
Other 13 (9.0) 1 (5.3) 5 (33.3) 0 7 (15.5) 0.066
Acute kidney injury, n (%) 60 (67.4) 7 (36.8) 9 (60.0) 6 (60.0) 38 (84.4) 0.002
Acute heart failure, n (%) 24 (27.0) 0 4 (26.7) 1 (10.0) 19 (42.2) 0.003
Severe sepsis, n (%) 63 (70.8) 10 (52.6) 8 (53.3) 9 (90.0) 36 (80.0) 0.032
Mechanical ventilation, n (%) 54 (60.7) 6 (31.6) 7 (46.7) 6 (60.0) 36 (80.0) 0.002
Comorbidities, n (%)
Diabetes mellitus 11 (12.3) 2 (10.5) 3 (20.0) 0 6 (13.3) 0.514
Chronic heart failure 4 (4.5) 0 2 (13.3) 0 2 (4.4) 0.256
Chronic renal failure 7 (7.9) 0 6 (40.0) 0 1 (2.2) <0.001
Urea, mmol/L 17.9 ± 12.7 13.6 ± 13.9 18.3 ± 12.6 16.3 ± 14.3 20.1 ± 11.8 0.301
Creatinine, μmol/L 287.5 ± 290.0 119.6 ± 138.3 496.7 ± 457.3 176.5 ± 191.0 313.2 ± 236.1 0.001
Oliguria, n (%) 45 (50.6%) 3 (15.8%) 11 (73.3%) 5 (50%) 26 (57.8%) 0.004
Urine output, mL/day 803 ± 796 1,309 ± 652 429 ± 388 916 ± 755 732 ± 878 0.008
Hemoglobin, g/L 103.5 ± 32.4 121.1 ± 34.2 109.9 ± 40.7 96.8 ± 16.0 95.5 ± 28.6 0.022
Platelet, ×109/L 136.0 ± 88.7 186.5 ± 70.2 165.7 ± 114.7 106.7 ± 75.7 111.2 ± 78.3 0.005
CRP, mg/L 133.4 ± 78.0 114.3 ± 70.4 105.4 ± 77.3 165.8 ± 73.2 141.7 ± 80.0 0.177
Albumin, g/L 30.3 ± 4.9 29.2 ± 5.1 32 ± 6.8 29.7 ± 3.5 30.3 ± 4.4 0.419
Bilirubin, mmol/La 27.6 (14.4-37.8) 23.3 (17.3-51.4) 10.0 (6.4-64.8) 45.5 (16.9-100.3) 27.6 (16.3-85.4) 0.304
Lactate, mmol/La 2.1 (1.3-3.8) 2.1 (1.5-3.4) 1.9 (1.3-3.8) 1.8 (1.3-3.5) 2.4 (1.3-3.9) 0.952
NT-ProBNP, pmol/La 274 (62-1,491) 15.4 (8.5-54) 591 (203-1,949) 61 (51-65) 817 (294-2,549) <0.001
APACHE II score 18.8 ± 8.6 13.6 ± 6.7 17.1 ± 7.5 15.5 ± 8.4 22.2 ± 8.3 <0.001
SOFA score 11.7 ± 6.0 6.6 ± 3.0 10.6 ± 5.1 10.7 ± 6.4 14.6 ± 5.6 <0.001
SAPS II 41.7 ± 18.5 19.7 ± 12.7 42.5 ± 18.3 34.8 ± 22.2 48.4 ± 17.0 <0.001
Fluid balance at day 1, mLa 1,134 (169-2,301) 966 (210-1,702) 1,734 (602-3,092) 1,514 (670-2,157) 1,118 (−334-2,499) 0.557
Cumulative fluid balance over 3 days, mLa 2,729 (676-4,883) 2,729 (676-4,883) 3,843 (2,515-4,824) 2,517 (514-5,571) 2,611(−993-5,282) 0.7935
aMedian (range). Fluid status: type 1, no overhydration and B-type natriuretic peptide (BNP) normal; type 2, no overhydration but BNP abnormal; type 3, overhydration
but BNP normal; type 4, overhydration and BNP abnormal. APACHE II, Acute Physiology and Chronic Health Evaluation II; CRP, C-reactive protein; NT-pro BNP, N-terminal
pro-B-type natriuretic peptide; SAPS II, Simplified Acute Physiology Score II; SOFA, Sequential Organ Failure Assessment.
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not calculated, which made the statistics analysis less
powerful.
Even though the study included only 89 critically ill
patients requiring CRRT and the statistical power of the
multivariate analyses of independent risk factors formortality was weak, the results implied that four classifi-
cations of fluid status according to two parameters
(BIVA and NT-Pro BNP) correspond to respective clinical
condition and treatment outcome. Therefore, the combin-
ation of BIVA and NT-pro BNP may have potential value
for assessment of fluid status in critically ill patients.
Table 2 Clinical outcomes between different types of fluid status before continuous renal replacement therapy
Fluid status Type 1 Type 2 Type 3 Type 4 Total P value
Number 19 15 10 45 89
Death within 3 days, n (%) 1 (5.3) 2 (13.3) 2 (20) 10 (22.2) 15 (16.9) 0.399
Death before discharge, n (%) 5 (26.3) 5 (33.3) 4 (40) 29 (64.4) 43 (48.3) 0.019
CRRT duration, day 5.1 ± 4.1 5.2 ± 3.0 8.5 ± 13.0 10.0 ± 8.7 8.0 ± 8.2 0.091
Recovery of renal function, n (%) 4 (57.1) 6 (67.7) 3 (50) 9 (23.7) 22 (36.7) 0.047
Fluid status: type 1, no overhydration and B-type natriuretic peptide (BNP) normal; type 2, no overhydration but BNP abnormal; type 3, overhydration but BNP normal;
type 4, overhydration and BNP abnormal. CRRT, continuous renal replacement therapy.
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needed to confirm our results.
Previous studies have reported the independent use of
BIVA and NT-pro BNP for assessment of fluid or vol-
ume status in critically ill patients. This report described
that overhydration and abnormal NT-pro BNP levels
corresponded to a poorer clinical condition and out-
come, which confirmed the roles of these parameters in
the assessment of fluid status as reported elsewhere
[9-12]. The combination of BIVA and NT-pro BNP was
generally used in patients with chronic stable fluid sta-
tus, such as those receiving maintenance hemodialysis,
and was reported to be a good reflection of fluid status
with good consistency [13,14]. However, our results
showed an inconsistency between the two parameters in
28% of patients receiving CRRT as well as associated dif-
ferences in clinical condition.
Increasingly, more studies have challenged the role of
single use of BNP for assessment of fluid status and pre-
diction of treatment outcome [15-18]. A recent study of
38 patients with severe burns, divided into high and lowFigure 1 Kaplan-Meier survival curves for patients with different fluid
of fluid status was determined by combination of bioimpedance vector analygroups according to BNP level on hospitalization day 3,
found that patients with higher BNP levels required less
fluid infusion and had lower Sequential Organ Failure
Assessment (SOFA) scores and better outcomes. This
result was explained by the authors as lower capillary
leakage in these patients resulting in retention of intravas-
cular fluid and a consequent increase in BNP level and
subsequent better outcome [19]. The prognostic value of
BNP in sepsis was investigated in a recent study, which
found no differences in BNP concentrations between
non-survivors and survivors of septic shock on any study
day [20].
The reason for these conflicting results may be due to
the reflection of BNP level on only cardiac reaction to
current fluid status, which is usually, but not always,
consistent with fluid status per se. Therefore, the con-
cept of ‘wet’ and ‘dry’ BNP was proposed [21,22], al-
though there is currently no clear means to differentiate
between the two. In the present study, we used the com-
bination of these parameters to categorize fluid status
into four types, each corresponding to a different clinicalstatus at start of continuous renal replacement therapy. The type
sis and serum N-terminal pro-B-type natriuretic peptide (NT-pro-BNP).
Table 3 Changes of fluid status and cumulative fluid balance over 3 days and outcomes (n = 70)
Fluid status before CRRT Fluid status 3 days later Total death,
n (%)Type 1 Type 2 Type 3 Type 4
Type 1 Cumulative fluid balance, mL 1,664 ± 1,971 3,832 ± 4,291 2,626 ± 3,732 870
Death, n (%) 1/10 (10%) 1/3 (33.3%) 2/3 (66.6%) 0/1 (0%) 4/17 (23.5%)
Type 2 Cumulative fluid balance, mL 1,566 2,365 ± 2,140 3,935 ± 2,130 5,974 ± 3,144
Death, n (%) 0/1 (0%) 1/4 (25%) 0/2 (0%) 2/4 (50%) 3/11 (27.3%)
Type 3 Cumulative fluid balance, mL 571 - 1,601 ± 1,147 3,242 ± 3,296
Death, n (%) 0/1 (0%) 0 1/3 (33.3%) 2/5 (40%) 3/9 (33.3%)
Type 4 Cumulative fluid balance, mL −1,380 ± 3,308 −1,159 ± 3,394 2,461 ± 2,844 2,613 ± 3,962
Death, n (%) 3/4 (75%) 1/5 (20%) 1/4 (25%) 14/20 (70%) 19/33 (57.6%)
Total death, n (%) 4/16 (25%) 3/12 (25%) 4/12 (33.3%) 18/30 (60%) 29/70 (41.4%)
Fluid status: type 1, no overhydration and B-type natriuretic peptide (BNP) normal; type 2, no overhydration but BNP abnormal; type 3, overhydration but BNP normal;
type 4, overhydration and BNP abnormal. CRRT, continuous renal replacement therapy.
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fluid status was associated with much higher BNP levels
than type 3 fluid status—591 (203 to 1,949) versus 61
(51 to 65) pmol/L—but conferring a similar mortality
with type 3 fluid status. Meanwhile, type 4 fluid sta-
tus was associated with only a slightly higher BNP
level than type 2—817 (294 to 2,549) versus 591 (203 to
1,949) pmol/L—but conferring a mortality much higher
than type 2 fluid status. As a summary of the results,
among patients with abnormal NT-pro BNP levels, those
with and without overhydration (BIVA abnormality) expe-
rienced quite different clinical conditions and outcomes.
Similarly, for patients with overhydration (BIVA abnor-
mality), there were differences in clinical conditions and
outcomes between those with and without abnormal NT-





APACHE II score 1.20 (1.11-1.29)
Acute kidney injury 2.90 (1.14-7.42)
Acute heart failure 2.82 (1.06-7.51)
Severe sepsis 3.62 (1.33-9.84)
Mechanical ventilation 4.50 (1.76-11.47)
Chronic renal failure 0.79 (0.17-3.74)
Chronic heart failure 3.38 (0.34-33.76)
Overhydration at day 1 3.60 (1.44-8.98)
High NT-ProBNP at day 1 2.54 (1.02-6.35)
Overhydration + high NT-ProBNP at day 1 3.88 (1.61-9.36)
Variables in the multivariate regression included age, gender, Acute Physiology and
failure, severe sepsis, mechanical ventilation, chronic renal failure, chronic heart fail
peptide (NT-ProBNP) level.the combined use of these two parameters for assessment
of fluid status.
The subdivision of fluid status, as presented in this
study, may provide a useful aid for the maintenance of
fluid balance. Especially, type 3 fluid status (manifested
as normal NT-pro BNP and abnormal BIVA) may indi-
cate overhydration but without vascular volume expan-
sion, a condition typically presented by patients with
nephrotic syndrome and in some receiving peritoneal
dialysis [11]. In regard to critical patients, these parame-
ters may reflect fluid accumulation, but only in extra-
vascular spaces, as usually observed in burn and septic
shock patients with capillary leakage syndrome caused
by a systemic inflammatory response or a fluid shift
caused by hypoalbuminemia [19,20]. Under this condi-
tion, removal of excess fluid through CRRT shouldor death (n = 89)
Adjusted multivariate regression
P value Odds ratio P value
0.006 1.02 (0.98-1.05) 0.374
0.649 0.72 (0.21-2.45) 0.597
<0.001 1.18 (1.08-1.29) <0.001
0.026 0.87 (0.19-4.05) 0.863
0.039 1.84 (0.44-7.81) 0.405
0.012 3.83 (0.74-19.74) 0.109
0.002 3.05 (0.86-10.88) 0.086
0.764 1.04 (0.06-19.44) 0.981
0.300 4.66 (0.15-143.72) 0.379
0.006 - -
0.046 - -
0.002 1.02 (0.30-3.38) 0.997
Chronic Health Evaluation II (APACHE II) score, acute kidney injury, acute heart
ure, and presence of overhydration plus high N-terminal pro-B-type natriuretic
Chen et al. Critical Care  (2015) 19:135 Page 7 of 8performed only along with infusion of adequate colloids
to shift fluid into vascular spaces. Moreover, type 2 fluid
status (manifested as normal BIVA and abnormal NT-pro
BNP) may imply cardiac dysfunction but no fluid over-
load. In this situation, proper ultrafiltration by CRRT is
essential to alleviate cardiac dysfunction, although over
ultrafiltration should be avoided to prevent volume deple-
tion. A recent study investigated the effect of the timing of
hemoconcentration on the survival of patients with de-
compensated heart failure receiving diuretic treatment
and reported that those with late versus early hemo-
concentration received higher average daily loop diur-
etic doses (P = 0.001), experienced greater weight loss
(P <0.001), had later transition to oral diuretics (P = 0.03),
and were discharged earlier (P <0.001). Late hemocon-
centration conferred a significant survival advantage (P =
0.009), whereas early hemoconcentration offered no sig-
nificant mortality benefit over no hemoconcentration.
Although BIVA was not performed in that study, it is
expected that patients with late hemoconcentration would
be type 4 fluid status, necessitating diuresis and removal
of fluid to improve outcome, but that patients with early
concentration likely have type 3 fluid status; thus, diuresis
and removal of fluid may result in volume depletion but
no benefit to outcome. Therefore, water removal via
CRRT ultrafiltration should be considerably aggressive
only in patients with type 4 fluid status.
Repeated measurement of BIVA and NT-pro BNP in
our study helped to elucidate the effect of change in
fluid status on treatment outcome. Owing to the small
sample size of this study, there is a lack of conclusive
results, but some findings were still noteworthy: for
patients with type 4 fluid status before CRRT, after
intervention, improvement of either BIVA or NT-pro
BNP versus no improvement conferred lower mortality;
however, those with improvement of both BIVA and NT-
pro BNP had the worst outcomes. A possible reason for
this poor outcome may be that over ultrafiltration oc-
curred in these patients, resulting in volume depletion.
Therefore, the combined use of NT-Pro BNP and BIVA
may avoid unnecessary overtreatment of patients with
unrecognized normohydration or dehydration resulting in
renal impairment.
Conclusions
Fluid status abnormalities were common among patients
receiving CRRT. Different types of fluid status distin-
guished by BIVA combined with serum NT-pro BNP
measurements corresponded to different clinical condi-
tions and treatment outcomes. For patients receiving
CRRT, real-time monitoring of fluid status by using
BIVA and NT-pro BNP may be useful in fluid manage-
ment by aiding in the identification of an optimal net
ultrafiltration rate during CRRT. However, owing to thesmall sample size and etiological heterogeneity of the
enrolled patients, future studies are needed to confirm the
value of the combined use of BIVA and NT-pro BNP.
Key message
 Different fluid status type prior to start of CRRT in
critically ill patients requiring CRRT, as determined
by the combined use of BIVA and serum NT-pro
BNP measurement, is associated with different
clinical conditions and treatment outcomes.
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